ライフサイエンスコーパス: visceral leishmaniasis

1 on into skin but disseminates to cause fatal visceral leishmaniasis.

2 a live attenuated vaccine candidate against visceral leishmaniasis.

3 evelopment of new therapeutic agents against visceral leishmaniasis.

4 ve agent of the tropical infectious disease, visceral leishmaniasis.

5 mployed a well-defined experimental model of visceral leishmaniasis.

6 ted in cultures recovered from patients with visceral leishmaniasis.

7 pool of sera from Brazilians with documented visceral leishmaniasis.

8 shmania chagasi, the cause of South American visceral leishmaniasis.

9 ing host immunity and liver pathology during visceral leishmaniasis.

10 d vaccinia virus-based vaccine against human visceral leishmaniasis.

11 No vaccine exists against visceral leishmaniasis.

12 it causes cutaneous, diffuse cutaneous, and visceral leishmaniasis.

13 ive CD8(+) T cells after vaccination against visceral leishmaniasis.

14 e pathogenesis as well as vaccine studies of visceral leishmaniasis.

15 se reported for subclinical canine and human visceral leishmaniasis.

16 orrelated with the probability of developing visceral leishmaniasis.

17 e immunity to Leishmania chagasi, a cause of visceral leishmaniasis.

18 tion is a risk factor for the development of visceral leishmaniasis.

19 d immunity and subsequent protection against visceral leishmaniasis.

20 the results of a vaccine trial against human visceral leishmaniasis.

21 inst parasite challenge in a murine model of visceral leishmaniasis.

22 with the life-threatening disease now called visceral leishmaniasis.

23 We tested this strategy in a murine model of visceral leishmaniasis.

24 ally) represent a major advance for treating visceral leishmaniasis.

25 ognostic utility of rK39 in detecting active visceral leishmaniasis.

26 activated late in the course of experimental visceral leishmaniasis.

27 parasites, in a Brazilian city endemic with visceral leishmaniasis.

28 ense regulation in the liver in experimental visceral leishmaniasis.

29 L. donovani, the etiological agent of deadly visceral leishmaniasis.

30 mania donovani, causative agent of the fatal visceral leishmaniasis.

31 protozoa, Leishmania donovani chagasi causes visceral leishmaniasis.

32 that are used to treat the parasitic disease visceral leishmaniasis.

33 herapeutic design and vaccine strategies for visceral leishmaniasis.

34 it with IL-4, plays a protective role during visceral leishmaniasis.

35 Leishmania donovani, the causative agent of visceral leishmaniasis.

36 plicated in the clinical expression of human visceral leishmaniasis, a disease-exacerbating T helper

37 curring beta-glucan immunomodulator, against visceral leishmaniasis, a fatal parasitic disease.

38 establish models for studying recurrence of visceral leishmaniasis, a growing problem in T cell-defi

39 In experimental visceral leishmaniasis, acquired resistance to intracell

40 Cutaneous and visceral leishmaniasis affect an estimated 1.5 million p

41 d, may be the first effective oral agent for visceral leishmaniasis, an intracellular protozoal infec

42 ishmania donovani parasites are the cause of visceral leishmaniasis and are transmitted by bites from

43 IL-17A is present in sera from patients with visceral leishmaniasis and decreases after successful tr

44 ctivation observed in patients with American visceral leishmaniasis and human immunodeficiency virus

45 Leishmania chagasi causes visceral leishmaniasis and, to a lesser extent, atypical

46 ing effects regulate outcome in experimental visceral leishmaniasis, and IL-10R blockade represents a

47 Leishmania donovani, the causative agent of visceral Leishmaniasis, and Leishmania tropica, the caus

48 me and response to treatment of experimental visceral leishmaniasis, and MAb targeting of T-cell cost

49 ania donovani, the main etiological agent of visceral leishmaniasis, and the autophagic machinery of

50 may overcome compromised T cell responses in visceral leishmaniasis, and this has an important implic

51 Patients with active visceral leishmaniasis are important reservoirs in the a

52 rotection found in vaccine studies of murine visceral leishmaniasis are significantly lower than for

53 of Leishmania donovani, the causal agent of visceral leishmaniasis, are conditionally lethal mutatio

54 The cumulative frequency of visceral leishmaniasis at 2 years did not differ signifi

55 ite burden in a 45-day BALB/c mouse model of visceral leishmaniasis at a dosage of 10 mg/kg/day as de

56 bundant in bone marrows of humans with acute visceral leishmaniasis but not in those of uninfected co

57 in Brazil has been used to control zoonotic visceral leishmaniasis but with little success.

58 s disease with 100% efficacy, and suppresses visceral leishmaniasis by 89% (vs 60% for VNI).

59 ote intracellular infection, including human visceral leishmaniasis, by disabling Th1 cell-type respo

60 -beta inhibits Th1-associated cure of murine visceral leishmaniasis caused by L. chagasi, independent

61 ature of many infectious diseases, including visceral leishmaniasis caused by Leishmania donovani.

62 of IL-10 in susceptibility to cutaneous and visceral leishmaniasis caused by Leishmania major and Le

63 Visceral leishmaniasis caused by the intracellular paras

64 Experimental visceral leishmaniasis, caused by infection of mice with

65 In experimental visceral leishmaniasis, caused by infection with the pro

66 Progressive disease in the hamster model of visceral leishmaniasis, caused by Leishmania donovani, i

67 In visceral leishmaniasis, chemotherapy probably seldom era

68 hough human immunodeficiency virus (HIV) and visceral leishmaniasis coinfection is recognized as a ma

69 ered significant protective immunity against visceral leishmaniasis compared with BCG alone.

70 eishmania donovani, the etiological agent of visceral leishmaniasis, confer polyamine auxotrophy to t

71 Clinical manifestations in canine visceral leishmaniasis (CVL) have not been clearly assoc

72 rial splenic aspirates from 27 patients with visceral leishmaniasis during monotherapy with interfero

73 y, transmission competence and the impact of visceral leishmaniasis elimination campaigns.Parasitemia

74 -line treatment in different formulations in visceral leishmaniasis endemic areas of Bihar, India.

75 protozoan parasites, the causative agent of visceral leishmaniasis, establish an infection partly by

76 h receptors potential therapeutic targets in visceral leishmaniasis for engagement (TLR4) or blockade

77 Consequently, an intradermal murine model of visceral leishmaniasis has been explored.

78 In human patients with active visceral leishmaniasis, high IgG levels are predictive o

79 However, in contrast to its role in human visceral leishmaniasis, IL-10 may not play a key immunos

80 In this model of visceral leishmaniasis, IL-6 appears to act in a suppres

81 of such polarized CD4(+) T cells facilitates visceral leishmaniasis in BALB/c mice in a clear contras

82 077 patients aged >/=14 years with confirmed visceral leishmaniasis in Bihar, eastern India, found th

83 etween IL-2R mutations and susceptibility to visceral leishmaniasis in children infected with Leishma

84 ensis is a primary vector of transmission of visceral leishmaniasis in China.

85 g a great perspective as a sensing system of visceral leishmaniasis in endemic regions.

86 Experimental visceral leishmaniasis in genetically susceptible mice i

87 is from dogs with clinical manifestations of visceral leishmaniasis in Governador Valadares, an endem

88 ys using crude antigens for the diagnosis of visceral leishmaniasis in human immunodeficiency virus t

89 hmania donovani, the main causative agent of visceral leishmaniasis in humans, and successfully appli

90 Leishmania donovani, the causative agent of visceral leishmaniasis in humans.

91 ular immunity and provide protection against visceral leishmaniasis in mice.

92 Control of human visceral leishmaniasis in regions where it is endemic is

93 d to reduce relapse of previously controlled visceral leishmaniasis in T cell-deficient hosts.

94 ling but scarring cutaneous lesions to fatal visceral leishmaniasis in which parasites disseminate to

95 In experimental visceral leishmaniasis, in which the tissue macrophage i

96 In patients with visceral leishmaniasis, increased levels of circulating

97 with cutaneous, visceral, and post-kala azar visceral leishmaniasis indicated that a majority of indi

98 In experimental visceral leishmaniasis, inhibition of interleukin 10 (IL

99 In experimental visceral leishmaniasis, interleukin (IL)-12 initiates co

100 Visceral leishmaniasis is a major cause of morbidity and

101 In Brazil, human and canine visceral leishmaniasis is caused by infection with Leish

102 sness of patients for the sand fly vector of visceral leishmaniasis is linked to parasites found in t

103 "Kala-azar" (or Indian Visceral Leishmaniasis) is a vector-borne infectious dis

104 Visceral leishmaniasis (kala-azar, KA) is the most sever

105 In stark contrast, the causative agent of visceral leishmaniasis, Leishmania donovani, does not pr

106 has been generated from a sand fly vector of visceral leishmaniasis, Lutzomyia longipalpis.

107 from self-healing cutaneous lesions to fatal visceral leishmaniasis, mucosal leishmaniasis and diffus

108 shmania chagasi, the cause of South American visceral leishmaniasis, must survive antimicrobial respo

109 ed on an index patient with thymoma, chronic visceral leishmaniasis, myasthenia gravis, and a marked

110 A database of records of cutaneous and visceral leishmaniasis occurrence was compiled from publ

111 The primary endpoint was clinical visceral leishmaniasis or post-kala-azar dermal leishman

112 a group of protozoal diseases that includes visceral leishmaniasis, or Kala Azar.

113 he relevance of asymptomatic and symptomatic visceral leishmaniasis patients as infection reservoirs.

114 We found that human visceral leishmaniasis patients exhibit elevated serum l

115 hat selection for parasite resistance within visceral leishmaniasis patients who have been exposed to

116 By using sera from Sudanese visceral leishmaniasis patients, we confirmed that the T

117 in sera of both cutaneous-leishmaniasis and visceral-leishmaniasis patients.

118 also displayed efficacy in a murine model of visceral leishmaniasis, reducing liver parasitemia by 37

119 -HLA-DQA1 HLA class II region contributes to visceral leishmaniasis susceptibility in India and Brazi

120 igher levels in bone marrow of patients with visceral leishmaniasis than in controls.

121 5 mm) had a significantly lower frequency of visceral leishmaniasis than non-responders (27/375 [7.2%

122 , suggesting shared genetic risk factors for visceral leishmaniasis that cross the epidemiological di

123 ce of kala-azar, a clinical manifestation of visceral leishmaniasis, to below 1 in 10,000 by 2020.

124 has been considered the main determinant of visceral leishmaniasis transmission.

125 lent, faces the highest burden world-wide of visceral leishmaniasis (VL) and human immunodeficiency v

126 Little is known about CD8 T cells in human visceral leishmaniasis (VL) and it is unclear if these c

127 +) T cell effector responses during clinical visceral leishmaniasis (VL) are associated with elevated

128 emic spread of Leishmania parasites in human visceral leishmaniasis (VL) are not well understood.

129 -27/TCCR pathway in the host defense against visceral leishmaniasis (VL) by monitoring the course of

130 eport a detrimental role of Ly6C(hi) iMOs in visceral leishmaniasis (VL) caused by Leishmania donovan

131 No vaccine is currently available for visceral leishmaniasis (VL) caused by Leishmania donovan

132 is also a vaccine antigen candidate against visceral leishmaniasis (VL) caused by Leishmania infantu

133 A periurban outbreak of visceral leishmaniasis (VL) caused by the protozoan Leis

134 Visceral leishmaniasis (VL) causes significant mortality

135 The neglected tropical disease (NTD) visceral leishmaniasis (VL) has been targeted by the WHO

136 , sodium stibogluconate) in the treatment of visceral leishmaniasis (VL) has fallen from more than 85

137 r residual spraying (IRS) is used to control visceral leishmaniasis (VL) in India, but it is poorly q

138 ne had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nepal, and Banglad

139 s study was to identify the risk factors for visceral leishmaniasis (VL) in renal transplant recipien

140 with human immunodeficiency virus (HIV) and visceral leishmaniasis (VL) in the VL-endemic areas of B

141 Visceral leishmaniasis (VL) is a fatal disease of the in

142 Visceral leishmaniasis (VL) is a form of leishmaniasis,

143 Visceral leishmaniasis (VL) is a life-threatening diseas

144 Visceral leishmaniasis (VL) is a potentially fatal paras

145 Visceral leishmaniasis (VL) is a serious parasitic disea

146 Visceral leishmaniasis (VL) is associated with severe im

147 Visceral leishmaniasis (VL) is caused by Leishmania dono

148 Active human visceral leishmaniasis (VL) is characterized by a progre

149 type 1 (Th1) and 17 (Th17) responses during visceral leishmaniasis (VL) is still unknown.

150 Visceral leishmaniasis (VL) is transmitted by sand flies

151 high miltefosine treatment failure rates for visceral leishmaniasis (VL) on the Indian subcontinent.

152 for the detection of Leishmania parasites in visceral leishmaniasis (VL) patients.

153 Visceral leishmaniasis (VL) remains a major public healt

154 Since the early 1980s, visceral leishmaniasis (VL) which is, in general, a rura

155 ficant number of individuals may progress to visceral leishmaniasis (VL), a deadly disease that threa

156 leishmaniasis (PKDL), a cutaneous sequela of visceral leishmaniasis (VL), develops in some patients a

157 diseases tegumentary leishmaniasis (TL) and visceral leishmaniasis (VL), is comparatively less well

158 Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is currently the first-line

159 te Leishmania donovani, a causative agent of visceral leishmaniasis (VL), require a potent host proin

160 During visceral leishmaniasis (VL), Th1-based inflammation is i

161 Leishmania donovani causes visceral leishmaniasis (VL), the second most deadly vect

162 to infection with L. donovani, the cause of visceral leishmaniasis (VL), was determined by Northern

163 oral drug available for treatment of Indian visceral leishmaniasis (VL), which was shown to have an

164 ent years to be highly efficient in treating visceral leishmaniasis (VL)-the life-threatening form of

165 ntileishmanial efficacy against experimental visceral leishmaniasis (VL).

166 le utility against the kinetoplastid disease visceral leishmaniasis (VL).

167 vani suggests that vaccination could prevent visceral leishmaniasis (VL).

168 recently approved for treatment of the fatal visceral leishmaniasis (VL).

169 t infects professional phagocytes and causes visceral leishmaniasis (VL).

170 potential first-in-class drug candidate for visceral leishmaniasis (VL).

171 nd cost-effective drugs for the treatment of visceral leishmaniasis (VL).

172 l C1 protein) and specific antibodies of the visceral leishmaniasis (VL).

173 mplications are sequelae of canine and human visceral leishmaniasis (VL).

174 Poor access to diagnosis stymies control of visceral leishmaniasis (VL).

175 lie many of the immunologic defects in human visceral leishmaniasis (VL).

176 no effective vaccine is available for human visceral leishmaniasis(VL) caused by Leishmania donovani

177 nsor construction, canine serum positive for visceral leishmaniasis was added to its surface and show

178 To identify susceptibility loci for visceral leishmaniasis, we undertook genome-wide associa

179 nly orally bioavailable drug for the disease visceral leishmaniasis, which is caused by the protozoan

180 gnificant risk factor for the development of visceral leishmaniasis, which results from skin inoculat